This agreement provides Cordyceps Sunshine with a pipeline asset but no near-term cash infusion. Monitor for any subsequent capital raising or milestone announcements to gauge execution progress. The going-concern qualification from the recent 20-F remains the dominant risk factor.
Price Chart
Executive Summary
Cordyceps Sunshine Biotech entered into a Cooperation and Development Agreement with Pet Sunshine Biological Research for the exclusive worldwide commercialization of its Antcin A (TFA-01) anti-inflammatory platform. The agreement is royalty-free with a 50/50 revenue split, but no upfront payment or immediate financial impact was disclosed. This is a strategic licensing deal for a pre-revenue biotech with a going-concern qualification from its recent 20-F filing.
Key Facts
- Exclusive worldwide commercialization and development rights for Antcin A (TFA-01) granted to Cordyceps Sunshine on a royalty-free basis.
- All commercial revenues from the platform will be split 50/50 between the two parties.
- No upfront payment, milestone payments, or minimum royalties were disclosed.
- The agreement does not transfer legal ownership of the platform assets.
- Cordyceps Sunshine remains subject to going-concern risk per its FY2025 20-F, with an accumulated deficit of $854,046 and negative working capital of $4.19M.
Financial Impact
No immediate financial consideration. Potential future revenue sharing if TFA-01 is commercialized, but timeframe and probability are highly uncertain.
Risk Factors
- No upfront cash, leaving the company's liquidity constraints unaddressed.
- Pre-revenue drug development stage with uncertain clinical and regulatory outcomes.
- Going-concern qualification and material weaknesses in internal controls per the prior 20-F.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-071711 |
| Document: ea0295908-6k_cordyceps.htm | 0001213900-26-071711 |
| Document: 0001213900-26-071711-index-headers.html | 0001213900-26-071711 |
| Document: 0001213900-26-071711-index.html | 0001213900-26-071711 |
| Document: 0001213900-26-071711.txt | 0001213900-26-071711 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 7w ago | 6-K | $9.18 $9.18 | · 0.00% | ▼ −0.08% | $9.18 (−0.00%) |
Jul 27, 2026 13w ago | 6-K | $9.18 $9.18 | · 0.00% | ▼ −3.38% | $9.18 (+0.00%) |
Jun 25, 2026 17w ago | 6-K | $9.18 $9.18 | · 0.00% | ▼ −0.53% | $9.18 (+0.00%) |
May 15, 2026 23w ago | 20-F | $9.18 $9.18 | · 0.00% | ▲ +1.58% | $9.18 (−0.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers